U.S. markets close in 4 hours 48 minutes

Samsung Biologics Co.,Ltd. (207940.KS)

KSE - KSE Delayed Price. Currency in KRW
Add to watchlist
912,000.00+9,000.00 (+1.00%)
At close: 3:30PM KST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close903,000.00
Open908,000.00
Bid927,000.00 x 0
Ask928,000.00 x 0
Day's Range907,000.00 - 938,000.00
52 Week Range624,000.00 - 948,000.00
Volume178,336
Avg. Volume159,351
Market Cap60.342T
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateOct 19, 2021 - Oct 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est499,500.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Samsung Biologics Reports Second Quarter 2021 Financial Results
      PR Newswire

      Samsung Biologics Reports Second Quarter 2021 Financial Results

      Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, today announced strong financial results for the second quarter of fiscal 2021.

    • Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy
      PR Newswire

      Kineta and Samsung Biologics Announce Development and Manufacturing Agreement for Anti-VISTA Antibody Immunotherapy

      Samsung Biologics (KRX: 207940.KS), one of the world's leading contract development and manufacturing organization (CDMO), signed a strategic partnership agreement with Kineta, Inc., a clinical-stage biotech company developing novel immunotherapies in oncology. Samsung Biologics will provide end-to-end CDMO service from cell line development, clinical drug substance, and drug product manufacturing services to support IND filing for KVA12.1, Kineta's novel anti-VISTA antibody in development for t

    • Samsung Biologics Issues Its First Annual Sustainability Report
      PR Newswire

      Samsung Biologics Issues Its First Annual Sustainability Report

      Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company's policies for an enhanced ESG management system and related plans. The report focuses on the company's commitment to taking part in social responsibility over the past decade and its future plans for the next ten years and beyond.